Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old

NCT07204457 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

1123

Enrollment

OTHER

Sponsor class

Conditions

Meningococcal Infections

Interventions

BIOLOGICAL: EG-MCV4
BIOLOGICAL: Menveo

Sponsor

EyeGene Inc.

Collaborators

[object Object]